From Analysis:
Neuroinflammation and microglial priming in early Alzheimer's Disease
Investigate mechanistic links between early microglial priming states, neuroinflammatory signaling, and downstream neurodegeneration in preclinical and prodromal AD.
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
The "Complement-Mediated Synaptic Protection" hypothesis proposes that excessive activation of the classical complement cascade — specifically the C1q-C3-C3aR and C4b pathways — drives synaptic loss in Alzheimer's disease by tagging synapses for microglial phagocytosis, and that complement pathway inhibition can preserve synapses and protect cognition. The central mechanistic claim is that Aβ oligomers and hyperphosphorylated tau activate the complement cascade in a neuronal activity-dependent manner, leading to localized C1q deposition on vulnerable synapses, C3 fragment opsonization, and microglial phagocytosis through CR3 receptors.
Curated pathway diagram from expert analysis
graph TD
A["Amyloid beta oligomers"]
B["Hyperphosphorylated tau"]
C["C1QA gene expression"]
D["C1q protein deposition"]
E["Classical complement activation"]
F["C3 convertase formation"]
G["C3b opsonization"]
H["C4b pathway activation"]
I["Microglial CR3 receptors"]
J["Synaptic phagocytosis"]
K["Synaptic loss"]
L["Cognitive decline"]
M["Complement inhibitors"]
N["C3aR antagonists"]
O["Neuroprotective therapy"]
A -->|"activates"| E
B -->|"triggers"| E
C -->|"upregulates"| D
D -->|"initiates"| E
E -->|"forms"| F
F -->|"generates"| G
E -->|"activates"| H
G -->|"targets synapses"| I
H -->|"enhances"| I
I -->|"promotes"| J
J -->|"causes"| K
K -->|"leads to"| L
M -->|"blocks"| E
N -->|"inhibits"| I
O -->|"prevents"| K
classDef mechanism fill:#4fc3f7
classDef pathology fill:#ef5350
classDef therapy fill:#81c784
classDef outcome fill:#ffd54f
classDef genetics fill:#ce93d8
class A,B,D,E,F,G,H mechanism
class I,J,K,L pathology
class M,N,O therapy
class C genetics
Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.
No debate transcripts available for this hypothesis.
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| 📄 | New Evidence | $0.445 | ▲ 2.7% | evidence_batch_update | 2026-04-13 02:18 |
| 📄 | New Evidence | $0.433 | ▲ 5.5% | evidence_batch_update | 2026-04-13 02:18 |
| ⚖ | Recalibrated | $0.410 | ▼ 1.4% | 2026-04-10 15:58 | |
| ⚖ | Recalibrated | $0.416 | ▼ 4.9% | 2026-04-10 15:53 | |
| 📄 | New Evidence | $0.437 | ▼ 8.8% | evidence_update | 2026-04-09 01:50 |
| 📄 | New Evidence | $0.479 | ▲ 17.1% | evidence_update | 2026-04-09 01:50 |
| ⚖ | Recalibrated | $0.409 | ▲ 0.3% | 2026-04-08 18:39 | |
| ⚖ | Recalibrated | $0.408 | ▼ 0.8% | 2026-04-04 16:38 | |
| ⚖ | Recalibrated | $0.411 | 2026-04-04 16:02 |
No clinical trials data available
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
h_494861d2["h-494861d2"] -->|targets| C1QA["C1QA"]
C1QA_1["C1QA"] -->|mediates| synaptic_pruning["synaptic_pruning"]
C1QA_2["C1QA"] -->|associated with mi| Alzheimer_s_disease["Alzheimer's disease"]
C1QA__C3__CX3CR1__CX3CL1["C1QA, C3, CX3CR1, CX3CL1"] -->|associated with| Alzheimer_s_disease_3["Alzheimer's disease"]
APOE["APOE"] -->|co associated with| C1QA_4["C1QA"]
C1QA__C3__CX3CR1__CX3CL1_5["C1QA, C3, CX3CR1, CX3CL1"] -->|co associated with| HIF1A__NFKB1["HIF1A, NFKB1"]
C1QA__C3__CX3CR1__CX3CL1_6["C1QA, C3, CX3CR1, CX3CL1"] -->|co associated with| CLOCK__ARNTL["CLOCK, ARNTL"]
C1QA__C3__CX3CR1__CX3CL1_7["C1QA, C3, CX3CR1, CX3CL1"] -->|co associated with| IL1B__TNFA__NLRP3["IL1B, TNFA, NLRP3"]
C1QA__C3__CX3CR1__CX3CL1_8["C1QA, C3, CX3CR1, CX3CL1"] -->|co associated with| IGFBPL1["IGFBPL1"]
C1QA__C3__CX3CR1__CX3CL1_9["C1QA, C3, CX3CR1, CX3CL1"] -->|co associated with| DNMT3A__HDAC1_2["DNMT3A, HDAC1/2"]
C1QA__C3__CX3CR1__CX3CL1_10["C1QA, C3, CX3CR1, CX3CL1"] -->|co associated with| GPR43__GPR109A["GPR43, GPR109A"]
C1QA_11["C1QA"] -->|co associated with| IGFBPL1_12["IGFBPL1"]
C1QA_13["C1QA"] -->|co associated with| Multiple["Multiple"]
C1QA_14["C1QA"] -->|co associated with| TNF_IL6["TNF/IL6"]
h_f19b8ac8["h-f19b8ac8"] -->|targets| C1QA_15["C1QA"]
style h_494861d2 fill:#4fc3f7,stroke:#333,color:#000
style C1QA fill:#ce93d8,stroke:#333,color:#000
style C1QA_1 fill:#ce93d8,stroke:#333,color:#000
style synaptic_pruning fill:#4fc3f7,stroke:#333,color:#000
style C1QA_2 fill:#ce93d8,stroke:#333,color:#000
style Alzheimer_s_disease fill:#ef5350,stroke:#333,color:#000
style C1QA__C3__CX3CR1__CX3CL1 fill:#ce93d8,stroke:#333,color:#000
style Alzheimer_s_disease_3 fill:#ef5350,stroke:#333,color:#000
style APOE fill:#ce93d8,stroke:#333,color:#000
style C1QA_4 fill:#ce93d8,stroke:#333,color:#000
style C1QA__C3__CX3CR1__CX3CL1_5 fill:#ce93d8,stroke:#333,color:#000
style HIF1A__NFKB1 fill:#ce93d8,stroke:#333,color:#000
style C1QA__C3__CX3CR1__CX3CL1_6 fill:#ce93d8,stroke:#333,color:#000
style CLOCK__ARNTL fill:#ce93d8,stroke:#333,color:#000
style C1QA__C3__CX3CR1__CX3CL1_7 fill:#ce93d8,stroke:#333,color:#000
style IL1B__TNFA__NLRP3 fill:#ce93d8,stroke:#333,color:#000
style C1QA__C3__CX3CR1__CX3CL1_8 fill:#ce93d8,stroke:#333,color:#000
style IGFBPL1 fill:#ce93d8,stroke:#333,color:#000
style C1QA__C3__CX3CR1__CX3CL1_9 fill:#ce93d8,stroke:#333,color:#000
style DNMT3A__HDAC1_2 fill:#ce93d8,stroke:#333,color:#000
style C1QA__C3__CX3CR1__CX3CL1_10 fill:#ce93d8,stroke:#333,color:#000
style GPR43__GPR109A fill:#ce93d8,stroke:#333,color:#000
style C1QA_11 fill:#ce93d8,stroke:#333,color:#000
style IGFBPL1_12 fill:#ce93d8,stroke:#333,color:#000
style C1QA_13 fill:#ce93d8,stroke:#333,color:#000
style Multiple fill:#ce93d8,stroke:#333,color:#000
style C1QA_14 fill:#ce93d8,stroke:#333,color:#000
style TNF_IL6 fill:#ce93d8,stroke:#333,color:#000
style h_f19b8ac8 fill:#4fc3f7,stroke:#333,color:#000
style C1QA_15 fill:#ce93d8,stroke:#333,color:#000
neurodegeneration | 2026-04-04 | completed